PUBLIC COMPANY
save$DAWNDay One Biopharmaceuticals, Inc.
$DAWN21.530.00%Brisbane, CA, USupdated 3mo ago
community read0 votes
pipeline
4
marketed
1
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
3Phase 11Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
- phase1To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
- phase2Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
- phase1Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
- phase2A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- —Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
🐶 Hiring Signal
News
- Opinion: STAT+: ‘What will I do with the time I have left?’: What it’s like to find out you might develop Alzheimer’s“What people fear isn’t the end of life, the demise of the animated body, but the demise of the mind,” writes Jason Karlawish.stat · 4d ago
- First U.S. bird flu death of the year after cattle exposureA person in Washington state has died from complications of the bird flu, the AP reported yesterday. It’s the first such death this year in the U.S., and the third…stat · 13d ago
- Opinion: How meditation helped me become a better doctor overnight“The inner work of meditation and self-inquiry can support the outer work of patient care,” writes a physician.stat · 14d ago
- STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technologyA STAT investigation found that Epic selectively withholds access to patient data, disadvantaging rival software developers and stymying innovation.stat · 20d ago
- EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shinesIn a Phase 1 study, treatment with Incyte's KRAS G12D inhibitor in combination with standard-of-care chemotherapy elicited an 89% confirmed objective response rate in patients with a type of pancre…biospace · 20d ago
- Opinion: How bad is healthy supposed to feel?“We shouldn't confuse illness and the hardships that come with living,” writes family nurse practitioner Kirsten Balin.stat · 22d ago
- Health insurance premiums jump 9%, and more Americans don’t have access to coverageWorking-age U.S. adults without health insurance rose in 2026. Half of all uninsured people did not seek needed care because of cost concerns, according to a new survey.stat · 25d ago
- Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xV…biospace · 29d ago
- ‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryBioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.fiercebiotech · 3mo ago
- Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journeyExpedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to propel its lead DPP1 inhibitor through phase 2.fiercebiotech · 3mo ago
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that